HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of “Hold” from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given a consensus rating of “Hold” by the five ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.80.

HCM has been the topic of a number of research analyst reports. Bank of America reduced their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Weiss Ratings downgraded HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 29th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Morgan Stanley set a $13.60 price target on HUTCHMED in a research report on Thursday, May 28th.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. boosted its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares during the period. Bank of America Corp DE raised its stake in HUTCHMED by 5.9% during the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after acquiring an additional 1,209 shares during the period. Crossmark Global Holdings Inc. raised its stake in HUTCHMED by 3.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after acquiring an additional 1,680 shares during the period. State Street Corp lifted its holdings in HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in HUTCHMED by 3.0% in the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after acquiring an additional 3,900 shares during the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Stock Performance

Shares of HCM stock opened at $11.44 on Friday. HUTCHMED has a one year low of $9.77 and a one year high of $19.50. The company’s 50-day simple moving average is $11.69 and its 200-day simple moving average is $13.56. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.